Vanguard Group Inc Ngm Biopharmaceuticals Inc Transaction History

Vanguard Group Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.17 - $1.92 $522,032 - $856,669	-446,182 Reduced 16.1%	2,324,392 $3.7 Million
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.31 $5,683 - $12,408	9,472 Added 0.34%	2,770,574 $2.38 Million
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $33,765 - $108,372	-32,158 Reduced 1.15%	2,761,102 $2.95 Million
Q2 2023 Aug 14, 2023	SELL	$2.44 - $4.53 $2.16 Million - $4.01 Million	-885,263 Reduced 24.07%	2,793,260 $7.23 Million
Q1 2023 May 15, 2023	SELL	$3.72 - $5.4 $3.02 Million - $4.38 Million	-810,626 Reduced 18.06%	3,678,523 $15 Million
Q4 2022 Feb 10, 2023	BUY	$3.41 - $12.93 $2.01 Million - $7.63 Million	589,852 Added 15.13%	4,489,149 $22.5 Million
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $6.25 Million - $8.77 Million	496,089 Added 14.58%	3,899,297 $51 Million
Q2 2022 Aug 12, 2022	BUY	$10.58 - $17.5 $4.11 Million - $6.8 Million	388,733 Added 12.9%	3,403,208 $43.6 Million
Q1 2022 May 13, 2022	BUY	$13.81 - $18.6 $652,356 - $878,626	47,238 Added 1.59%	3,014,475 $46 Million
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $24.3 Million - $31 Million	1,407,112 Added 90.19%	2,967,237 $52.6 Million
Q3 2021 Nov 12, 2021	BUY	$20.15 - $26.19 $3.45 Million - $4.48 Million	171,051 Added 12.31%	1,560,125 $32.8 Million
Q2 2021 Aug 13, 2021	BUY	$15.06 - $30.03 $20.9 Million - $41.7 Million	1,389,074 New	1,389,074 $27.4 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.